The Importance of Median Progression-Free Survival in Oncology Clinical Trials

Tanios S. Bekaii-Saab

Subscribe

The Importance of Median Progression-Free Survival in Oncology Clinical Trials

Interview with the Innovators

Pancreatic Cancer Patient Education

Videos

Tanios S. Bekaii-Saab, MD

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Shubham Pant, MD

Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX

Michael Pishvaian, MD, PhD

Associate Professor of Oncology
Johns Hopkins University, Washington, DC

In this third installment, Michael Pishvaian, MD, PhD, and Tanios Bekaii-Saab, MD, discuss why median progression-free survival is so important when considering the various transformational trials in pancreatic cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

The Importance of Median Progression-Free Survival in Oncology Clinical Trials

Related Items

Sponsored By

Subscribe Today!

I'd like to receive:

We Value Your Feedback! Tell Us How You Consume Content